Laurens V. Beerepoot

Author

Also Known As

Joos Heisterkamp, L Beerepoot, L V Beerepoot, L. Beerepoot, L. J. Beerepoot, L. V. Beerepoot, L.V. Beerepoot, Laurens Beerepoot, Laurens V Beerepoot, Laurens V. Beerepoot

190

Publications

5.8K

Citations

H-Index

Concepts

All Affiliations

Elisabeth-TweeSteden Ziekenhuis Radboud University Nijmegen University Medical Center Utrecht The Netherlands Cancer Institute Catharina Ziekenhuis

About

Laurens V. Beerepoot is an author at Elisabeth-TweeSteden Ziekenhuis specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	3.7K
2	Health Sciences	4	4	550
3	Public Health	3	3	115
4	Cell Biology	2	2	480
5	Nursing	1	1	25

Laurens V. Beerepoot

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients Salo Ooft, Fleur Weeber, Krijn K. Dijkstra, Science Translational Medicine Gastrointestinal OncologyPdo TestMedicineColorectal CancerPathology	2019	769
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp, The Lancet Oncology Neuro-oncologyOncologySingle-agent BevacizumabMetronomic TherapyClinical Trials	2014	738
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. Manabu Kuroki, Emile E. Voest, Shiro Amano, Journal of Clinical Investigation Redox BiologyTumor BiologyOxidative StressInflammationAngiogenesis	1996	420
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance Kristy J. Gotink, Henk J. Broxterman, Mariëtte Labots, Clinical Cancer Research	2011	335
Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients Laurens V. Beerepoot, Niven Mehra, Joost S.P. Vermaat, Annals of Oncology Endothelial Cell PathobiologyAngiogenesisEndothelial CellsProgressive DiseaseMedicine	2003	244
Patterns of metachronous metastases after curative treatment of colorectal cancer Yvette R.B.M. van Gestel, Ignace H. J. T. de Hingh, Myrthe P. P. van Herk‐Sukel, Cancer Epidemiology Surgical OncologyGastrointestinal OncologyMedicinePathologyColorectal Cancer	2014	230
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer Alessandro Leal, Nicole C.T. van Grieken, Doreen N. Palsgrove, Nature Communications	2020	222
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer Astrid E. Slagter, Edwin P. M. Jansen, Hanneke W.M. van Laarhoven, BMC Cancer	2018	147
Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid Tumors Laurens V. Beerepoot, Sandra A. Radema, Els O. Witteveen, Journal of Clinical Oncology	2006	114

Page 1